Should raising high-density lipoprotein cholesterol be a matter of debate?

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism

Background:

• High-density lipoprotein cholesterol (HDL-C) is an established inverse predictor of coronary heart disease.
• Conflicting trial results regarding HDL-C interventions create confusion about its clinical utility.
• Patient selection and treatment effects on HDL quality, not just quantity, may explain discrepancies.

Purpose of the Study:

• To review HDL-C trial outcomes and clarify the clinical relevance of HDL quantity and function.
• To explore the concept of 'dysfunctional' HDL in specific disease states.
• To guide future research and therapeutic strategies for cardiovascular risk reduction.

Main Methods:

• Review of existing clinical trial data on HDL-C interventions.
• Analysis of factors influencing HDL-C levels and function.
• Discussion of the clinical implications of HDL particle quality.

Main Results:

• HDL-C quantity alone may not fully capture cardiovascular risk.
• HDL particle functionality is clinically relevant and can be impaired in conditions like diabetes and acute coronary syndromes.
• Some interventions may increase HDL-C levels without improving its cardioprotective function.

Conclusions:

• Focusing solely on increasing HDL-C levels may be insufficient for cardiovascular risk management.
• Improving HDL particle functionality is crucial, alongside achieving adequate HDL-C levels.
• Future therapeutic strategies should consider both the quantity and quality of HDL particles.